Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update – Markets Insider
Reurope |
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
Markets Insider As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the … Zacks Premium Investment Service – Zacks.com |
